SINOPHARM GROUP 1/5/O.N. (X2S1) - Total Liabilities
Based on the latest financial reports, SINOPHARM GROUP 1/5/O.N. (X2S1) has total liabilities worth €256.20 Billion EUR (≈ $299.53 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SINOPHARM GROUP 1/5/O.N. annual equity growth to track the company's year-over-year net asset growth rate.
SINOPHARM GROUP 1/5/O.N. - Total Liabilities Trend (2021–2025)
This chart illustrates how SINOPHARM GROUP 1/5/O.N.'s total liabilities have evolved over time, based on quarterly financial data.
SINOPHARM GROUP 1/5/O.N. Competitors by Total Liabilities
The table below lists competitors of SINOPHARM GROUP 1/5/O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ningbo Shuanglin Auto Parts
SHE:300100
|
China | CN¥3.70 Billion |
|
Applied Opt
NASDAQ:AAOI
|
USA | $419.44 Million |
|
Brederode SA
BR:BREB
|
Belgium | €1.19 Million |
|
Versigent PLC
NYSE:VGNT
|
USA | $4.77 Billion |
|
Solvay SA
BR:SOLB
|
Belgium | €5.06 Billion |
|
Boyd Group Services Inc.
TO:BYD
|
Canada | CA$1.76 Billion |
|
HMS Networks AB (publ)
ST:HMS
|
Sweden | Skr3.04 Billion |
|
China National Medicines Corp Ltd
SHG:600511
|
China | CN¥15.19 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SINOPHARM GROUP 1/5/O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of SINOPHARM GROUP 1/5/O.N..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SINOPHARM GROUP 1/5/O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SINOPHARM GROUP 1/5/O.N. (2021–2025)
The table below shows the annual total liabilities of SINOPHARM GROUP 1/5/O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €256.20 Billion ≈ $299.53 Billion |
-3.74% |
| 2024-12-31 | €266.14 Billion ≈ $311.15 Billion |
+1.17% |
| 2023-12-31 | €263.08 Billion ≈ $307.56 Billion |
+3.29% |
| 2022-12-31 | €254.71 Billion ≈ $297.78 Billion |
+8.04% |
| 2021-12-31 | €235.76 Billion ≈ $275.63 Billion |
-- |
About SINOPHARM GROUP 1/5/O.N.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more